MOH250117C250000
- 84.50
- 0.000.00%
Molina Healthcare Newsroom
Molina Health Is Maintained at Buy by Truist Securities
Molina Healthcare Analyst Ratings
Truist Financial Maintains Molina Healthcare(MOH.US) With Buy Rating, Announces Target Price $370
Molina Health Coverage Assumed by JP Morgan at Neutral Vs Previous Rating of Overweight
Molina Health Price Target Cut to $350.00/Share From $378.00 by JP Morgan
Molina Healthcare Analyst Ratings
J.P. Morgan Initiates Molina Healthcare(MOH.US) With Hold Rating, Announces Target Price $350
Jefferies Maintains Molina Healthcare(MOH.US) With Hold Rating, Cuts Target Price to $312
Wells Fargo Maintains Molina Healthcare(MOH.US) With Hold Rating, Cuts Target Price to $340
Wells Fargo Cuts Price Target on Molina Healthcare to $340 From $362, Maintains Equalweight Rating
Molina Healthcare (MOH) Receives a Hold From Wells Fargo
Jefferies Adjusts Price Target on Molina Healthcare to $348 From $341, Maintains Hold Rating
Truist Financial Maintains Molina Healthcare(MOH.US) With Buy Rating
TD Cowen Maintains Molina Healthcare(MOH.US) With Buy Rating, Maintains Target Price $378
A Quick Look at Today's Ratings for Molina Healthcare(MOH.US), With a Forecast Between $362 to $372
Molina Healthcare (MOH) Receives a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)
Molina Healthcare: Hold Rating Amid Growth Challenges and Legislative Risks
Barclays Maintains Molina Healthcare(MOH.US) With Hold Rating, Maintains Target Price $372
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)